KORRO BIO, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.46 USD | -5.45% |
|
-7.45% | -1.02% |
| May. 15 | HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating | MT |
| May. 14 | Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer | MT |
ETFs positioned on Korro Bio, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 0 M€ | 0.00% | - |
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the bodyâs natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Companyâs first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
50.2
USD
Average target price
126.2
USD
Spread / Average Target
+151.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.02% | 465M | |
| +63.57% | 62.59B | |
| -2.15% | 41.18B | |
| +44.76% | 40.29B | |
| -8.93% | 27.9B | |
| +12.19% | 26.21B | |
| -21.85% | 19.09B | |
| +3.62% | 13.08B | |
| +25.39% | 12.26B | |
| +27.30% | 12.05B |
- Stock Market
- Equities
- KRRO Stock
- Funds and ETFs Korro Bio, Inc.
